ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $8.00 Consensus Target Price from Analysts

Key Points

• ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of "Buy" from eight brokerages, with seven analysts recommending a buy and one giving a strong buy rating.
• Institutional investors are showing increased interest, with Osaic Holdings increasing their stake by 59.6% and BNP Paribas Financial Markets by 28.4% during the second quarter.
• For its most recent quarter, ProQR reported losses of $0.14 per share, missing estimates, with revenues of $4.33 million against a consensus of $5.01 million.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has received an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $8.00.

PRQR has been the subject of several recent research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th. Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, August 8th. Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Finally, JMP Securities reissued a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently added to or reduced their stakes in PRQR. Osaic Holdings Inc. increased its position in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 4,500 shares during the period. Bank of America Corp DE increased its position in shares of ProQR Therapeutics by 11.8% in the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock valued at $217,000 after acquiring an additional 8,621 shares during the period. Jane Street Group LLC purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at about $30,000. Squarepoint Ops LLC increased its position in shares of ProQR Therapeutics by 16.3% in the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock valued at $220,000 after acquiring an additional 11,623 shares during the period. Finally, OneDigital Investment Advisors LLC increased its position in shares of ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 12,500 shares during the period. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Stock Up 6.3%

Shares of NASDAQ PRQR traded up $0.13 during mid-day trading on Friday, reaching $2.19. 379,866 shares of the company were exchanged, compared to its average volume of 348,651. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The stock has a market capitalization of $230.41 million, a PE ratio of -4.76 and a beta of 0.36. The company's 50 day moving average price is $2.19 and its 200 day moving average price is $1.86.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%.The company had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. On average, sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).